Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Exclusive: Novavax executives could get big payday even if vaccine fails

07/22/2020 | 08:37am EST
FILE PHOTO: U.S. Senate hearing on plan to research, manufacture and distribute coronavirus vaccine, on Capitol Hill in Washington

One of the leading U.S. firms developing a coronavirus vaccine, Novavax Inc, has awarded executives stock options that could pay out tens of millions of dollars even if its efforts fail.

Novavax CEO Stanley Erck and three other executives would earn the options, worth $101 million at Tuesday's closing stock price, if the company's vaccine candidate enters a mid-stage clinical trial - regardless of its eventual success, according to a company filing. The incentive plan, which has not been previously reported, allows the executives to start exercising the options a year after Novavax starts the so-called Phase 2 trial, as it expects to do soon.

Starting the Phase 2 trial is no guarantee the vaccine candidate will make it to market. Novavax would have to successfully complete more extensive Phase 3 trials and win approval from the U.S. Food and Drug Administration.

The Gaithersburg, Maryland-based company has not brought a vaccine to market in its 33-year history. But its market value has rocketed from $250 million to $8 billion in about five months on news of its coronavirus vaccine prospects. The Trump administration has given Novavax $1.6 billion under its "Operation Warp Speed" program to accelerate coronavirus vaccine development.

Graphic - Novavax shares soar on vaccine prospects:

In a statement to Reuters, Novavax said the stock options were awarded to retain its top talent and recognize their intense effort. "Launching a Phase 2 trial quickly and under these circumstances is a significant achievement," the company said.

The company did not address why the options were tied to mid-stage trials rather than the vaccine's ultimate success.

Executive compensation experts and patient advocates said the Novavax options skew incentives for executives by tying a massive payout to a short-term, interim milestone.

"Drug companies like Novavax are getting billions of dollars from taxpayers to develop a COVID-19 vaccine, so it's certainly concerning to see their executives get massive payouts before we know if the vaccine actually works," said Eli Zupnick, a spokesman for consumer watchdog Patients Over Pharma.

Sanjai Bhagat, a University of Colorado finance professor and an expert on executive pay plans, called the options an example of poor corporate governance and misguided incentive compensation.

"Phase 2 is nice," he said. "But you want the company focused on the actual vaccine. What investors care about - and what we as general members of society care about - is the long-term success."

SHIFTING OPTIONS

Stock options have fallen out of favor across corporate America as a way to reward executives amid concerns that they encourage management strategies that promote short-term stock gains at the expense of long-term growth. As a result, equity compensation has been shifting towards share awards that are structured to align executives more closely with their investors and cannot be gamed for a big profit as easily as options.

In the boom-and-bust biotech industry, more companies grant options that vest over time, but few tie them to performance goals, making Novavax's arrangement unusual. Only seven of 125 U.S. biotech companies had pegged option awards to achieving drug development milestones in 2019 and 2018, according to an analysis conducted for Reuters by ISS Corporate Solutions, the consulting arm of corporate governance consultant Institutional Shareholder Services.

Executives at another leading vaccine maker, Moderna Inc, have come under scrutiny for regular stock sales that have netted executives tens of millions of dollars since its share value spiked.

Whether Novavax executives reap fortunes from the options remains to be seen. The company's prospects for selling a coronavirus vaccine should be more clear by the time executives can start exercising the options, which could be shortly more than a year from now, according to the company's anticipated clinical trial schedule. Novavax has said it expects to start Phase 2 trials soon and enter Phase 3 trials by year end.

While vaccines traditionally could take a decade to develop, many experts expect a much faster process with the current crop of COVID-19 vaccine candidates. Their confidence stems from the effort's massive scale and new development technologies.

Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security, said it is "within the realm of possibility" for Novavax or another major developer to have a COVID-19 vaccine fully approved and in use within a year. For that to happen, however, "everything would have to go perfectly" in trials and in regulatory reviews, he said.

If development drags on longer - and stock values stay high - Novavax executives could be in a position to cash in on continuing vaccine hopes regardless of whether it ultimately delivers on them.

HUGE UPSIDE POTENTIAL

Erck's stock options would be worth $48.6 million if they could be exercised at Novavax's closing price of $140.69 per share on Tuesday. That would be 20 times his total compensation in 2019 of $2.4 million and much higher than the $25 million received last year by Alex Gorsky, the CEO of Johnson & Johnson, one of the largest U.S. healthcare and consumer products companies and a rival of Novavax in the race for a vaccine.

Even before the stock options were awarded in April, Erck was well positioned to capitalize on the rally in Novavax shares. Erck, who has been CEO since 2011, holds options and other awards totaling roughly $64 million, with $25 million that can be cashed out now, according to an analysis by pay consultant Farient Advisors.

Novavax disclosed in its filings that the awards to its executives were among 2.5 million stock options, currently worth $304 million, granted to all of its employees in April. The company filing did not make clear what performance requirements apply to the options for employees beyond the four executives, and a spokesperson declined to comment. Novavax had 165 full-time employees as of March 6.

At the company's June 25 annual meeting, 88% of shareholder votes cast supported its executive pay and 82% of votes favored changes allowing Novavax to issue the new options.

A smaller Novavax shareholder, Allianz Global Investors, voted against both of the pay items. Allianz Global analyst Robbie Miles said the executives already had adequate incentives and he would have preferred to reward them based on how Novavax shares perform. He said some investors' concerns, however, may be alleviated should the company's coronavirus vaccine succeed.

"If they save humanity," Miles said, "there may be less focus on the pay construction, for sure."

By Ross Kerber and Jessica DiNapoli


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ALLIANZ SE 0.03% 198.58 Delayed Quote.-9.08%
JOHNSON & JOHNSON 0.85% 150.27 Delayed Quote.3.02%
MODERNA, INC. -3.01% 152.52 Delayed Quote.679.75%
NOVAVAX, INC. -2.25% 126.25 Delayed Quote.3,145.23%
All news about NOVAVAX, INC.
12/02North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research
RE
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/01AstraZeneca partner sticks with two full dose regimen in COVID trials in Indi..
RE
11/30Nikola, JetBlue fall; Moderna, Novavax rise
AQ
11/30Novavax expects delayed U.S. COVID-19 vaccine trial to start in coming weeks
RE
11/30NOVAVAX : Announces COVID-19 Vaccine Clinical Development Progress
AQ
11/30Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the comin..
RE
11/30NOVAVAX : Announces COVID-19 Vaccine Clinical Development Progress
AQ
11/30Novavax Announces COVID-19 Vaccine Clinical Development Progress
GL
More news
Financials (USD)
Sales 2020 550 M - -
Net income 2020 -310 M - -
Net cash 2020 465 M - -
P/E ratio 2020 -23,4x
Yield 2020 -
Capitalization 6 456 M 6 456 M -
EV / Sales 2020 10,9x
EV / Sales 2021 1,83x
Nbr of Employees 522
Free-Float 97,6%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 186,20 $
Last Close Price 126,25 $
Spread / Highest target 76,6%
Spread / Average Target 47,5%
Spread / Lowest Target -40,6%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Gregory F. Covino Chief Financial Officer & Executive Vice President
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.3,145.23%6 456
MODERNA, INC.679.75%60 354
CELLTRION, INC.109.94%46 823
LONZA GROUP AG54.02%45 349
IQVIA HOLDINGS INC.10.42%32 710
SEAGEN INC.56.86%32 316